Iranian Journal of Otorhinolaryngology

Iranian Journal of Otorhinolaryngology

Effects of Vitamin D Supplementation on Recurrence of Nasal Polyposis after Endoscopic Sinus Surgery

Document Type : Original

Authors
Farnaz Hashemian 1
Sonya Sadegh 1
Javaneh Jahanshahi 1
Mohamad Ali Seif Rabiei 2
Farshad Hashemian 3
1 Department of Otolaryngology-Head and Neck Surgery, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
2 Department of Health Sciences, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran.
3 Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
10.22038/ijorl.2019.37766.2241
Abstract
Introduction:
Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a relatively common disease with serious impacts on patient quality of life. Recurrence of polyps after functional endoscopic sinus surgery (FESS) is a dilemma. Vitamin D3 (VD3) is known to inhibit the proliferation of nasal polyp-derived fibroblasts. The present study aimed to investigate the effects of oral VD3 on the recurrence of polyposis after FESS.
Materials and Methods:
This triple-blind placebo-controlled clinical trial was conducted on 40 patients with CRSwNP who did not respond to medical treatment and were candidates for FESS. In addition, the patients had VD3 insufficiency. Following the surgery, all the patients received routine treatment (i.e., fluticasone spray, irrigation, cefixime 400 mg daily for 10 days, and montelukast for a month). Moreover, the case group received oral VD3 tablets 4000 IU (single daily dose) for a month, and the control group received placebo in the same manner. The Sino-Nasal Outcome Test (SNOT-22) and Meltzer endoscopic grading scores were recorded at months 1, 3, and 6 after the study.
Results:
In this study, 6 months following the intervention, the severity of polyposis was reported to be significantly lower in the VD3 group compared to the placebo group based on SNOT-22 (16.25±10.16 in the VD3 group vs. 47.45±13.55 in the placebo group; P<0.001) and Meltzer scores (0.50±0.60 in the VD3 group vs. 2.65±0.93 in the placebo group; P<0.001). No adverse effects were observed in the case group.                     
Conclusion:
This study showed the efficacy and safety of vitamin D supplementation in the reduction of polyposis recurrence after FESS in patients with CRSwNP.
Keywords
Chronic rhinosinusitis
Endoscopy
Nasal polyposis
Vitamin D3
  1. Hashemian F, Baghbanian N, Majd Z, Rouini M, Jahanshahi J, Hashemian F. The effect of thyme honey nasal spray on chronic rhinosinusitis: a double-blind randomized controlled clinical trial. Eur Arch Otorhinolaryngol 2015; 272(6):1429–35.
  2. Flint P, Haughey B, Lund V, Niparko J, Robbins K, Thomas J, et al. Cummings Otolaryngology–Head & Neck Surgery. 6th ed. Philadelphia, PA; 2015: 2778-803.
  3. Pawankar R. Nasal polyposis: an update: editorial review. CurrOpin Allergy ClinImmunol 2003; 3(1): 1-6.
  4. Schleimer RP, Kato A, Peters A, Conley D, Kim J, Liu MC, et al. Ithelium, inflammation, and immunity in the upper airways of humans: studies in chronic rhinosinusitis. Proc Am ThoracSoc 2009; 6(3):288–94.
  5. Hammad H, Lambrecht BN. Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma. Nat Rev Immunol 2008; 8(3):193–204.
  6. Oyer SL, Nagel W, Mulligan JK. Differential expression of adhesion molecules by sinonasal fibroblasts among control and chronic rhinosinusitis patients. Am J Rhinol Allergy 2013; 27(5):381–6.
  7. Agrawal T, Gupta GK, Agrawal DK. Vitamin D supplementation reduces airway hyperresponsiveness and allergic airway inflammation in a murine model. ClinExp Allergy 2013; 43(6):672–83.
  8. Rostkowska-Nadolska B, Fraczek M, Gawron W, Latocha M. Influence of vitamin D (3) analogues in combination with budesonid R on proliferation of nasal polyp fibroblasts. ActaBiochim Pol 2009; 56(2):235-42.
  9. Selvaraj P, Harishankar M, Singh B, Banurekha VV, Jawahar MS. Effect of vitamin D3 on chemokine expression in pulmonary tuberculosis. Cytokine 2012; 60(1):212–19.
  10. Saji F, Nonaka M, Pawankar R. Expression of RANTES by IL-1 beta and TNF-alpha stimulated nasal polyp fibroblasts. AurisNasus Larynx 2000; 27(3): 247-52.
  11. Fraczek M, Rostkowska-Nadolska B, Kusmierz D, Zielinska A, Rok J, Sliupkas-Dyrda E, et al. Vitamin D analogs decrease in vitro secretion of RANTES and enhance the effect of budesonide. Adv Med Sci 2012; 57(2): 290–5.
  12. Mullol J, Roca-Ferrer J, Alobid I, Pujols L, Valero A, Xaubet A, et al. Effect of desloratadine on epithelial cell granulocytemacrophage colony-stimulating factor secretion and eosinophil survival. ClinExp Allergy 2006; 36(1): 52-8.
  13. Hackstein H, Thomson AW. Dendritic cells. emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 2004; 4(1):24–34.
  14. Searing DA, Zhang Y, Murphy JR, Hauk PJ, Goleva E, Leung DY. Decreased serum vitamin D levels in children with asthma are associated with increased corticosteroid use. J Allergy ClinImmunol 2010;125(5): 995-1000.
  15. Ciaccio CE, Portnoy JM. Vitamin D insufficiency and risk of severe asthma exacerbations. Curr Allergy Asthma Rep. 2010; 10(6): 387-8.
  16. Schlosser RJ, Carroll WW, Soler ZM, Pasquini WN, Mulligan JK. Reduced sinonasal levels of 1α-hydroxylase are associated with worse quality of life in chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol 2016;6(1):58-65.
  17. Wang LF, Lee CH, Chien CY, Chen JY, Chiang FY, Tai CF.Serum 25-hydroxyvitamin D levels are lower in chronic rhinosinusitis with nasal polyposis and are correlated with disease severity in Taiwanese patients.Am J Rhinol Allergy 2013;27 (6): 162-5.
  18. Faruk EM, Yousef MM, Mohamed T. Does vitamin D have protective effect on human nasal polyposis: histological and immunohistochemical study. J HistolHistopathol 2014;1:2.
  19. Newton JR, Ah-See KW. A review of nasal polyposis. TherClin Risk Manag 2008; 4(2): 507-12.
  20. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012; 50(1): 1-12.
  21. Konstantinidis I, Fotoulaki M, Iakovou I, Chatziavramidis A, Mpalaris V, Shobat K, et al. Vitamin D₃ deficiency and its association with nasal polyposis in patients with cystic fibrosis and patients with chronic rhinosinusitis. Am J Rhinol Allergy 2017;31(6):395-400.
  22. Faghih Habibi A, Gerami H, Banan R, KazemnezhadE, Khoshkhat P, AlaieAlamouti H, et al. Serum 25-Hydroxy Vitamin D in Chronic Rhinosinusitis with and Without Nasal Polyposis: A Case-Control Stud. Iranian Journal of Otorhinolaryngology, 2019;31(1), 19-24.
  23. Mostafa Bel-D, Taha MS, Abdel Hamid T, Omran A, Lotfi N. Evaluation of vitamin D levels in allergic fungal sinusitis, chronic rhinosinusitis, and chronic rhinosinusitis with polyposis. Int Forum Allergy Rhinol. 2016;6(2):185-90.
  24. Carroll WW, Schlosser RJ, O'Connell BP, Soler ZM, Mulligan JK. Vitamin D deficiency is associated with increased human sinonasal fibroblast proliferation in chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol 2016;6(6):605-10.
  25. Sansoni ER, Sautter NB, Mace JC, Smith TL, Yawn JR, Lawrence LA, et al. Vitamin D3 as a novel regulator of basic fibroblast growth factor in chronic rhinosinusitis with nasal polyposis. Int Forum Allergy Rhinol 2015;5(3):191-6.
  26. Schlosser RJ, Soler ZM, Schmedes GW, Storck K, Mulligan JK. Impact of vitamin D deficiency upon clinical presentation in nasal polyposis.Int Forum Allergy Rhinol2014;4(3):196-9.
  27. Stokes PJ, Rimmer J. The relationship between serum vitamin D and chronic rhinosinusitis: A systematic review. Am J Rhinol Allergy 2016;30 (1):23-8.
Iranian Journal of Otorhinolaryngology
Volume 32, Issue 1 - Serial Number 108
January and February 2020
Pages 21-28